Heung-Moon Chang

FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab

Wu Zhang, Michael A. Gordon, Anne M. Schultheis et al. · Journal of Clinical Oncology · 2007 · 478 citations

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

James J. Harding, Jia Fan, Do‐Youn Oh et al. · The Lancet Oncology · 2023 · 201 citations

Medicine, Biliary Cancer, Pathology +5

Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays

Kab Choong Kim, Young Wha Koh, Heung-Moon Chang et al. · Annals of Surgical Oncology · 2011 · 178 citations

Tumor Biology, Medicine, Pathology +9

Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis

JiHoon Kang, Inhwan Hwang, Changhoon Yoo et al. · Investigational New Drugs · 2018 · 144 citations

Oncology, Pancreatic Cancer, Gastrointestinal Oncology +8

APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant <i>nab</i>-paclitaxel plus gemcitabine (<i>nab</i>-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

Margaret A. Tempero, Michele Reni, Hanno Riess et al. · Journal of Clinical Oncology · 2019 · 143 citations

Surgical Oncology, Cancer Management, Pharmacotherapy +17